Literature DB >> 16799344

A comparison of effects of alfentanil, fentanyl, and remifentanil on hemodynamic and respiratory parameters during stereotactic brain biopsy.

Hülya Bilgin1, Elif Başağan Moğol, Ahmet Bekar, Remzi Işçimen, Gülsen Korfali.   

Abstract

The aim of this study was to compare the effects of 3 different sedative-analgesic regimens in patients with intracranial mass lesions undergoing stereotactic brain biopsy. A 135 outpatients with American Society of Anesthesiologists I to II were divided into 3 groups: group A (n = 45) received a loading dose of IV alfentanil 7.5 microg/kg followed by infusion rate of 0.25 microg/kg/min; group F (n = 45) received a bolus dose of 1 microg/kg IV fentanyl and repeated as needed; and group R (n = 45) received infusion of 0.05 microg/kg/min remifentanil. Target level of sedation was 3 to 4 of the Ramsay Sedation Scale. Systolic and diastolic blood pressure, heart rate, respiratory rate, peripheric oxygen saturation (SpO2), and end-tidal carbon dioxide were recorded at different stages of the procedures. The patients in group F had significantly lower mean heart rate than those in groups A and R, but this was not in the limits of the bradycardia. The patients in group A had significantly lower mean SpO2 than those in the other groups, but mean SpO2 values did not drop below 94%. There were no significant differences in end-tidal carbon dioxide and respiratory rate values among the groups. Our results suggest that all 3 regimens have relatively similar hemodynamic and respiratory responses. The use of bolus fentanyl technique caused less hemodynamic stability. The continuous infusion technique of remifentanil or alfentanil provided better control on hemodynamic parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799344     DOI: 10.1097/01.ana.0000210998.10410.2e

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  7 in total

1.  Rescue treatment for noninvasive ventilation failure due to interface intolerance with remifentanil analgosedation: a pilot study.

Authors:  Monica Rocco; Giorgio Conti; Elisa Alessandri; Andrea Morelli; Gustavo Spadetta; Amalia Laderchi; Carmela Di Santo; Samanta Francavilla; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2010-09-17       Impact factor: 17.440

2.  Remifentanil-based sedation to treat noninvasive ventilation failure: a preliminary study.

Authors:  Jean-Michel Constantin; Eric Schneider; Sophie Cayot-Constantin; Renaud Guerin; Francois Bannier; Emmanuel Futier; Jean-Etienne Bazin
Journal:  Intensive Care Med       Date:  2006-11-14       Impact factor: 17.440

Review 3.  Analgesia without sedatives during colonoscopies: worth considering?

Authors:  S Eberl; B Preckel; P Fockens; M W Hollmann
Journal:  Tech Coloproctol       Date:  2012-06-06       Impact factor: 3.781

4.  Effect of naloxone on intravenous fentanyl patient-controlled analgesia after laparoscopic cholecystectomy.

Authors:  Jun Zheng; Wen Han; Xiao-Dong Han; Xiao-Yuan Ma; Pengbo Zhang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

5.  The effect of sedation and/or analgesia as rescue treatment during noninvasive positive pressure ventilation in the patients with Interface intolerance after Extubation.

Authors:  Yue-Nan Ni; Ting Wang; He Yu; Bin-Miao Liang; Zong-An Liang
Journal:  BMC Pulm Med       Date:  2017-09-15       Impact factor: 3.317

6.  Comparison of the effects of target-controlled infusion-remifentanil/midazolam and manual fentanyl/midazolam administration on patient parameters in dental procedures.

Authors:  Doug Lobb; Nazila Ameli; Silvia Ortiz; Hollis Lai
Journal:  J Dent Anesth Pain Med       Date:  2022-03-25

7.  Remifentanil prevents withdrawal movements caused by intravenous injection of rocuronium.

Authors:  Byung In Choi; Seung Ho Choi; Yang-Sik Shin; Sung Jin Lee; Kyung Bong Yoon; Seo Kyung Shin; Ki-Young Lee
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.